Increased serum levels of soluble CD14 indicate stable multiple sclerosis
Increased serum levels of soluble CD14 indicate stable multiple sclerosis
复制标题
DOI：
10.1016/j.jneuroim.2006.09.002
复制
发表时间：
2006-12-01
影响因子：
3.3
通讯作者：
Reindl, Markus
中科院分区：
文献类型：
--
作者：
Lutterotti, Andreas;Kuenz, Bettina;Reindl, Markus
本研究的目的是评估可溶性 CD14 (sCD14) 在多发性硬化症 (MS) 中的可能作用。我们发现，与神经系统和健康对照相比，多发性硬化症患者通过 ELISA 测量的 sCD14 血清水平较高。在 MS 组中，与原发进展型 MS 相比，复发缓解型和继发进展型 MS 中 sCD14 水平升高。此外，在疾病稳定期间，sCD14 浓度增加。用干扰素-β 治疗后还检测到 sCD14 表达增加。总之，我们报告的证据表明，多发性硬化症患者血清 sCD14 水平升高，并且与复发性多发性硬化症患者的疾病活动度呈负相关。 (c) 2006 Elsevier B.V. 保留所有权利。
The aim of this study was to evaluate a possible role of soluble CD14 (sCD14) in multiple sclerosis (MS). We found that sCD14 serum levels measured by ELISA were higher in MS patients compared to neurological and healthy controls. Within the MS group sCD14 levels were increased in relapsing-remitting and secondary progressive MS compared to primary progressive MS. Furthermore, sCD14 concentrations were increased during stable disease. An increased expression of sCD14 was also detected after treatment with interferon-beta. In summary, we report evidence that serum sCD14 levels are increased in MS and correlate inversely with disease activity in relapsing MS patients. (c) 2006 Elsevier B.V. All rights reserved.